Skip to content

GSK Wins Early FDA Nod for Nelkarmi

The US regulator has cleared GSK's targeted lung cancer drug Nelkarmi ahead of schedule, the second approval to come from the Nuvalent acquisition, though the shares were little changed in early trade.

GSK (LON: GSK), the London-listed drugmaker, has won accelerated US approval for its lung cancer drug Nelkarmi, ahead of the regulator’s target date. The FDA, the US drug regulator, cleared neladalkib for previously treated ALK-positive non-small cell lung cancer, GSK said in a statement at 7am today.

GSK shares stood at 1866p as of 08:31 UK time, down 0.16% from yesterday’s close of 1869p, on a delayed quote. They fell 3.1% in yesterday’s session from Monday’s close of 1929.5p, the top of a three-month closing range that bottomed at 1735.5p.

GSK.LSE

Accelerated approval is conditional clearance based on early data, pending confirmatory trials. It covers adults with locally advanced or metastatic disease previously treated with alectinib alone, or with two or more ALK TKIs (targeted cancer drugs) plus platinum chemotherapy. The decision came before the 27th of November target date, following Breakthrough Therapy and Orphan Drug designations.

The approval rests on ALKOVE-1, a phase I/II trial with no comparator arm. The confirmed overall response rate, the share of patients whose tumours shrank, was 49% (33 of 67) after alectinib only and 32% (50 of 155) after two or more TKIs plus chemotherapy. Intracranial response, shrinkage within the brain, was 55% and 26%. Hepatotoxicity, or liver toxicity, was the main safety signal, and 5% of patients permanently discontinued, most often because of it.

Line chart of GSK's daily closing share price in pence over three months, rising to a peak on Monday before falling on Tuesday
GSK share price, daily close in pence, 17 August to 17 November 2026

GSK agreed on the 9th of June to buy US cancer-drug developer Nuvalent for $10.6bn. Nelkarmi follows Jideytro (zidesamtinib), approved in July for ROS1-positive lung cancer. Tony Wood, GSK’s chief scientific officer, said:

Nelkarmi is our second new medicine approved in lung cancer this year.

Tony Wood, GSK

The commercial case will rest on launch uptake and on ALKAZAR, a phase III trial in patients who have not had a TKI before.

Asktraders News Team
Asktraders News Team
Team Member

The AskTraders Analyst Team features experts in technical and fundamental analysis, as well as traders specializing in stocks, forex, and cryptocurrency.

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.